Strategic and commercial update
AIM Rule 26
The website contains all information which is required to be disclosed in accordance with Rule 26 of the AIM Rules for Companies.
Description of the business & Investment strategy
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations which modulate the human microbiome and can be used as food ingredients, supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
OptiBiotix has developed a portfolio of intellectual property in and around this field of research, consisting of patents, trademarks and novel microbial strains. Further intellectual property is expected to be developed or acquired as opportunities arise from existing and future research and development.
OptiBiotix has been working with leading international key opinion leaders and entered into a research agreement with the University of Reading on 18 September 2012 to generate novel microbiome modulating compounds using reverse enzyme synthesis. All intellectual property arising from this research is owned by OptiBiotix.
The names of the directors and biographical details
Directors' responsibilities & Committees
Country of incorporation and main country of operations
Current constitutional documents
- Number of AIM securities in issue
- Significant shareholders
- TR1 notifications
- Shares not in public hands
- Restrictions in transfer of AIM securities
- Shareholder circulars
- UK City Code on Takeovers and Mergers
Page last updated: 16 February 2024
ProBiotix Health anticipating "big commercial opportunities" during 2023
Group CEO Stephen O’Hara and CEO Steen Anderson | 04 January 2023